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RESEARCH
Can harmonisation of outcomes bridge 
the translation gap for pre-clinical research? 
A systematic review of outcomes measured 
in mouse models of type 2 diabetes
Nicola L. Harman1* , Adrián Sanz‑Moreno2 , Stamatia Papoutsopoulou3 , Katie A. Lloyd4 , 
Kamar E. Ameen‑Ali5 , Malcolm Macleod6  and Paula R. Williamson1 
Abstract 
Background: In pre‑clinical research, systematic reviews have the potential to mitigate translational challenges by 
facilitating understanding of how pre‑clinical studies can inform future clinical research. Yet their conduct is encum‑
bered by heterogeneity in the outcomes measured and reported, and those outcomes may not always relate to the 
most clinically important outcomes. We aimed to systematically review outcomes measured and reported in pre‑clini‑
cal in vivo studies of pharmacological interventions to treat high blood glucose in mouse models of type 2 diabetes.
Methods: A systematic review of pre‑clinical in vivo studies of pharmacological interventions aimed at addressing 
elevated blood glucose in mouse models of type 2 diabetes was completed. Studies were screened for eligibility and 
outcomes extracted from the included studies. The outcomes were recorded verbatim and classified into outcome 
domains using an existing outcome taxonomy. Outcomes were also compared to those identified in a systematic 
review of registered phase 3/4 clinical trials for glucose lowering interventions in people with type 2 diabetes.
Results: Review of 280 included studies identified 532 unique outcomes across 19 domains. No single outcome, or 
domain, was measured in all studies and only 132 (21%) had also been measured in registered phase 3/4 clinical trials. 
A core outcome set, representing the minimum that should be measured and reported, developed for type 2 diabe‑
tes effectiveness clinical trials includes 18 core outcomes, of these 12 (71%) outcomes were measured and reported in 
one or more of the included pre‑clinical studies.
Conclusions: There is heterogeneity of outcomes reported in pre‑clinical research. Harmonisation of outcomes 
across the research pathway using a core outcome set may facilitate interpretation, evidence synthesis and transla‑
tional success, and may contribute to the refinement of the use of animals in research.
Systematic review registration: The study was prospectively registered on the PROSPERO Database, registration number 
CRD42018106831
Keywords: Type 2 diabetes, Pre‑clinical research, Mouse models of type 2 diabetes, Core outcome set, Translational 
research, Clinical research, Pre‑clinical systematic review
© The Author(s) 2020. This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, 
adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and 
the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material 
in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material 
is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the 
permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creat iveco 
mmons .org/licen ses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creat iveco mmons .org/publi cdoma in/
zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
Background
Clinical trials are undertaken to evaluate the effective-
ness and safety of treatments in defined populations, and 
use pre-defined outcome measures. However, there is 
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often marked variability between trials in the outcomes 
measured and reported which contributes to research 
waste through the inability to compare findings and syn-
thesise evidence from multiple trials [1]. These issues 
can be addressed through the use of a core outcome set 
(COS), defined as “the minimum [set of outcomes] that 
should be measured and reported in all clinical trials of 
a specific condition” [2]. Indeed, in the case of rheuma-
toid arthritis, a core outcome set has increased the con-
sistency of outcome reporting, and use of the COS has 
increased over time [3]. There are currently 337 COSs 
spanning 31 disease areas that have been developed for 
clinical research or practice or both [4]. However, despite 
the uptake of COSs in clinical trials, little is known about 
their relationship to the outcomes measured at other 
stages of the research pathway.
In pre-clinical research there is a recognised issue in 
the ability of animal models to predict effectiveness in 
humans, with large variability in translational success 
rates [5–7]. Pre-clinical systematic reviews have been 
proposed as a way to improve understanding of pre-
clinical effectiveness and how this can inform clinical 
trials [8–10]. Yet, as in clinical trials, the ability to sys-
tematically review the literature is impacted by issues 
of methodological rigour and further compounded by 
heterogeneity in the outcomes measured and reported 
[1, 11]. Initiatives to improve the reporting of methodo-
logical details, for instance, the Animal Research: Report-
ing In  Vivo Experiments (ARRIVE) guidelines [12], do 
not consider the choice of study outcome(s), that may 
impact not only on the ability to systematically compare 
and contrast the study results but also on the translat-
ability of pre-clinical research to later phase trials. While 
the STAIR criteria for preclinical stroke research does 
address this issue, their requirements are rather broad 
[13]. We sought to explore the issue of outcome hetero-
geneity in pre-clinical research and the potential appli-
cation of a COS using type 2 diabetes research as a case 
study. Type 2 diabetes is a global health concern; it has 
been estimated that 700 million people aged 20–79 will 
be affected by diabetes by 2045, the majority of these 
cases being type 2 diabetes [14–16]. There are a number 
of established animal models for the study of type 2 dia-
betes [17, 18] with mouse models offering several advan-
tages, including ease of induction of type 2 diabetes, a 
relatively short breeding span, and availability of physi-
ological and invasive testing [19]. Mice are widely used 
in endocrine and metabolic research and, if all research 
areas are taken into account, represent the most widely 
used animal model in pre-clinical research [20]. We 
aimed to systematically review outcomes measured in 
pre-clinical research for type 2 diabetes using a mouse 
model, and to compare these to outcomes measured in 
clinical trials of glucose lowering interventions in type 2 
diabetes [21]. Finally we examine the extent of the appli-
cability of an existing COS [22] for type 2 diabetes in pre-
clinical research.
Methods
Search strategy
Relevant pre-clinical animal studies were identified with 
a combined search of MEDLINE, PubMED and SCOPUS 
using search terms specific to each database (Table  1). 
Searches were undertaken on the 16th July 2018.
Returned entries were exported to Endnote, screened 
for duplicates and then uploaded into the CAMA-
RADES-NC3Rs Preclinical Systematic Review & Meta-
analysis Facility (SYRF) (www.syrf.org.uk, accessed 3rd 
March-2020) for screening.
The database held on www.precl inica ltria ls.eu was also 
searched for ongoing registered trials of glucose lowering 
interventions for diabetes, but none were identified (July 
2018).
The study protocol, including the search strategy, 
was  prospectively registered on the PROSPERO inter-
national prospective register of systematic reviews 
(https ://www.crd.york.ac.uk/prosp ero/displ ay_recor 
d.php?ID=CRD42 01810 6831).
Eligibility criteria
Publications reporting a pharmacological intervention 
aimed at lowering blood glucose in a mouse model for 
type 2 diabetes were eligible for inclusion. Eligible mouse 
models included dietary induced, chemically induced, 
monogenic or polygenic models. To be eligible for inclu-
sion, studies must have been undertaken in the context of 
type 2 diabetes and not solely in other related metabolic 
disorders, for example, metabolic syndrome, obesity or 
insulin resistance. There were no restrictions on the year 
of publication.
Studies were excluded if they met any of the follow-
ing exclusion criteria: publications reporting the use 
of mouse models in other related metabolic disorders 
but not in type 2 diabetes; publications focusing on the 
prevention of type 2 diabetes only; publications report-
ing interventions in other animal models; publications 
reporting in  vitro studies only; publications reporting 
non-pharmacological interventions for type 2 diabetes; 
publications primarily focused on interventions for com-
plications of type 2 diabetes (e.g. retinopathy, neuropa-
thy, cardiovascular disease, gastroparesis); publications 
reporting interventions exclusively for type 1 diabetes 
or gestational diabetes; studies that are solely mechanis-
tic. Publications were also excluded if they used a mouse 
model inappropriate for the study of type 2 diabetes 
including, but not limited to, non obese diabetic mice, 
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Akita mice, viral induced diabetes, alloxan induced dia-
betes, high dose streptozotocin (100–200 mg/kg). Strep-
tozotocin models were included if a low dose was used 
to induce diabetes and the study specified the use of the 
model in the context of type 2 diabetes.
Assessment of study eligibility
Abstracts were reviewed in duplicate by a team of 
reviewers (NH, AS-M, SP, KL and KAA). Due to the large 
number of included abstracts, a 25% sample (in 10-year 
blocks) was taken forward to full text review. At full text 
review, a 10% duplicate screening batch check was com-
pleted for each reviewer before proceeding with single 
review. Where disagreement or uncertainty about inclu-
sion of a study was noted, the reviewers discussed the 
study before reaching a decision. No study required third 
reviewer arbitration.
Data extraction
Data extraction from included full texts was under-
taken by NH. Data on the year of publication, region of 
work and the mouse model used was extracted along 
with the outcomes measured. Data on outcomes was 
extracted from the methods and results sections of 
papers along with figures, tables and Additional file  1 
where available. In cases of composite outcomes, all 
component outcomes were extracted. Where data on 
a specific adverse event was collected the outcome was 
listed twice, once as an adverse event and once as the 
specific outcome.
Outcome classification
Each outcome was reviewed and grouped with other 
outcomes if they measured the same aspect albeit using 
a different method. Each outcome was categorised 
according to the COMET taxonomy [23]. This tax-
onomy comprises 38 domains under five areas (death, 
physiological/clinical, life impact, resource use and 
adverse events). Outcome grouping and categorisation 
was cross checked by AS-M.
Table 1 Search strategies
MEDLINE
Line Search term
1 Exp models,animal/
2 Exp animals/
3 Exp humans/
4 1 OR 2
5 4 NOT 3
6 Mouse ab.ti.tw
7 5 AND 6
8 Pyrazines/or Glucagon‑Like Peptide 1/or Adaman‑
tane/or Blood Glucose/or exp Hypoglycemic 
Agents/or Pyrrolidines/or Dipeptidyl‑Peptidase 
IV Inhibitors/or Dipeptidyl Peptidase 4/or Diabe‑
tes Mellitus, Type 2/or DPP‑4.mp. or Triazoles/
9 7 AND 8
Pub Med
 1 Exp models,animal/
 2 Exp humans/
 3 1 NOT 2
 4 Mouse ab.ti.tw
 5 3 AND 4
 6 Pyrazines/or Glucagon‑Like Peptide 1/or Adaman‑
tane/or Blood Glucose/or exp Hypoglycemic 
Agents/or Pyrrolidines/or Dipeptidyl‑Peptidase 
IV Inhibitors/or Dipeptidyl Peptidase 4/or Diabe‑
tes Mellitus, Type 2/or DPP‑4 or Triazoles/
 7 5 AND 6
SCOPUS
 (((TITLE‑ABS‑KEY (mouse) AND TITLE‑ABS‑KEY (glucose))) AND (TITLE‑ABS‑KEY (diabetes))) AND (INDEXTERMS (nonhuman)) AND (LIMIT‑TO (SUB‑
JAREA, “PHAR”))
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Comparison with clinical trials
Outcomes were then compared to those identified from 
a previous review of phase 3/4 registered clinical trials 
[21] and to those included in the core outcome set for 
type 2 diabetes [22].
Fig. 1 PRISMA flow diagram
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Results
Characteristics of included studies
A systematic review was performed, to identify relevant 
pre-clinical in vivo studies using a mouse model of type 
2 diabetes. A sample of 25% of included abstracts was 
assessed for eligibility at the full text stage and out-
comes extracted from 280 eligible studies (Fig.  1). All 
studies used a mouse model of type 2 diabetes with 
the majority (63%) using a genetic model, for exam-
ple, KK-Ay or Lepr db/dbmice. The characteristics of 
the included studies are described in Table  2.  A full 
list of the included studies is available in Additional 
file 1-included studies.  
Outcomes measured in pre‑clinical studies
A total of 2874 individual outcomes were extracted 
with a median of 8 outcomes per trial (range 1–46). 
Each outcome was reviewed and categorised using the 
COMET taxonomy [23] (Table 3). Outcomes were also 
tagged if they had also been measured in phase 3/4 
clinical trials in Type 2 diabetes identified in a previous 
systematic review [21].
The 2874 outcomes represented 532 unique out-
comes across 19 domains. Of the unique outcomes, 205 
(39%) represented outcomes relevant to the mecha-
nism of drug action rather than safety or efficacy. No 
single outcome was measured in all studies. The most 
frequently represented domain was “metabolism and 
nutrition” with all but one study (279/280) measuring 
one or more outcomes within the domain. Within this 
domain, 90% (253/279) measured blood or plasma glu-
cose or both; and 99% (277/279) either blood/plasma 
glucose, tissue glucose, glycaemic control, glucose tol-
erance, hypoglycaemia or urinary glucose. Also within 
the “metabolism and nutrition” domain just under half 
of studies (44%) measured one or more lipid or lipo-
protein markers of cardiovascular disease risk. Emerg-
ing cardiovascular risk markers such as biomarkers of 
oxidative stress were less frequently measured (9% of 
studies). 171 of 280 studies (61%) reported “general 
outcomes” (not attributed to a certain body system), for 
example, outcomes relating to body weight or composi-
tion (166/280, 59%).164 of 280 studies (59%) included 
an outcome in the “endocrine outcomes” domain and of 
these 151 (92%) included an outcome relating to insu-
lin, c-peptide or glucagon. Adverse events or effects 
were less frequently reported with only 7% of trials 
including one or more outcomes in this domain.
Comparison with outcomes measured in later phase 
clinical trials
All domains measured in pre-clinical in  vivo stud-
ies had also been measured in phase 3/4 clinical trials. 
The distribution of outcomes across the COMET tax-
onomy  domains was similar between pre-clinical and 
clinical studies with the exception of “vascular”, “cardiac”, 
“adverse events” and “delivery of care” outcomes that 
were more prevalent in phase 3/4 trials; and “endocrine 
outcomes”, that were more frequently measured pre-
clinically. The clinical trials also included outcomes in 
an additional 11 domains (Table  3). Of these additional 
domains, “economic”, “hospital”, “role functioning” and 
“perceived health status” could only relate to human 
intervention studies.
Importantly, of the 532 unique outcomes reported pre-
clinically, only 21% had also been measured in type 2 
diabetes clinical trials. This may reflect the prevalence of 
mechanistic outcomes in pre-clinical studies, or greater 
feasibility for measuring certain outcomes in the pre-
clinical setting compared with clinical trials.
Comparison with an existing core outcome set
Core outcome sets (COS) represent the minimum set of 
outcomes that should be measured and reported in every 
clinical trial of a specific area of health [24]. Their pur-
pose is to reduce the heterogeneity in outcomes meas-
ured in clinical trials of a particular condition, facilitate 
evidence synthesis, and promote the measurement of 
outcomes relevant to all stakeholders. A COS for glucose 
Table 2 Description of included studies
N (%)
Year
 1980–1989 8 (3)
 1990–1999 23 (8)
 2000–2009 89 (32)
 2010–2018 160 (57)
Region of work
 Africa 5 (2)
 Asia 142 (51)
 Europe 76 (27)
 North America 55 (20)
 South America 2 (1)
Mouse model
 Chemically induced diabetes 38 (14)
 Diet induced diabetes 39 (14)
 Genetic model 176 (63)
 Mixed models–chemical and diet 12 (4)
 Mixed models–chemical and genetic 3 (1)
 Mixed models–diet and genetic 12 (4)
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Table 3 Comparison of pre-clinical and clinical trial outcomes by domain
Outcome domain Pre‑clinical in vivo mouse studies Phase 3/4 clinical trials [20]
Total number of unique 
outcomes within domain 
(verbatim outcomes)
Number of studies 
reporting one or more 
outcomes in the domain 
(%)
Total number of unique 
outcomes within domain 
(verbatim outcomes)
Number of studies 
reporting one or more 
outcomes in the domain 
(%)
1. Mortality/survival 2 (7) 7 (2.5) 2 (3) 3 (2.2)
2. Blood and lymphatic 
system outcomes
12 (23) 13 (4.6) 14 (19) 9 (6.5)
3. Cardiac outcomes 6 (11) 8 (2.9) 11 (56) 20 (14.5)
4. Congenital, familial and 
genetic outcomes
0 (0) 0 (0) 0 (0) 0 (0)
5. Endocrine outcomes 32 (324) 164 (58.6) 14 (50) 31 (22.5)
6. Ear and labyrinth out‑
comes
0 (0) 0 (0) 0 (0) 0 (0)
7. Eye outcomes 0 (0) 0 (0) 2 (2) 2 (1.4)
8. Gastrointestinal outcomes 7 (9) 7 (2.5) 12 (20) 5 (3.6)
9. General outcomes 26 (296) 171 (61.1) 40 (146) 65 (47.1)
10. Hepatobiliary outcomes 23 (123) 70 (25) 12 (25) 12 (8.7)
11. Immune system out‑
comes
35 (84) 26 (9.3) 32 (73) 28 (20.3)
12. Infection and infestation 
outcomes
0 (0) 0 (0) 7 (8) 4 (2.9)
13. Injury and poisoning 
outcomes
0 (0) 0 (0) 0 (0) 0 (0)
14. Metabolism and nutrition 
outcomes
317 (1816) 279 (99.6) 105 (582) 121 (87.7)
15. Musculoskeletal and con‑
nective tissue outcomes
21 (42) 19 (6.8) 2 (2) 2 (1.4)
16. Outcomes relating 
to neoplasms: benign, 
malignant and unspeci‑
fied (including cysts and 
polyps)
0 (0) 0 (0) 0 (0) 0 (0)
17. Nervous system out‑
comes
14 (18) 7 (2.5) 16 (16) 6 (4.3)
18. Pregnancy, puerperium 
and perinatal outcomes
0 (0) 0 (0) 0 (0) 0 (0)
19. Renal and urinary out‑
comes
19 (45) 30 (10.7) 53 (76) 27 (19.6)
20. Reproductive system and 
breast outcomes
0 (0) 0 (0) 0 (0) 0 (0)
21. Psychiatric outcomes 2 (3) 3 (1.1) 2 (2) 2 (1.4)
22. Respiratory, thoracic and 
mediastinal outcomes
2 (5) 4 (1.4) 3 (11) 23 (16.7)
23. Skin and subcutaneous 
tissue outcomes
0 (0) 0 (0) 1 (1) 1 (0.7)
24. Vascular outcomes 8 (9) 8 (2.9) 56 (134) 52 (37.7)
25. Physical functioning 4 (27) 17 (6.1) 3 (7) 5 (3.6)
26. Social functioning 0 (0) 0 (0) 4 (6) 5 (3.6)
27. Role functioning 0 (0) 0 (0) 3 (6) 3 (2.2)
28. Emotional functioning/
wellbeing
0 (0) 0 (0) 23 (28) 8 (5.8)
29. Cognitive functioning 1 (2) 2 (0.7) 16 (22) 2 (1.4)
30. Global quality of life 0 (0) 0 (0) 2 (5) 4 (2.9)
31. Perceived health status 0 (0) 0 (0) 2 (4) 4 (2.9)
32. Delivery of care 1 (1) 1 (0.4) 18 (60) 30 (21.7)
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lowering interventions for type 2 diabetes has been 
developed [22] and the outcomes measured pre-clinically 
were compared to this. The core outcome set includes 18 
outcomes, and of these 17 could potentially be measured 
in a mouse model. Twelve (71%) of these core outcomes 
were represented to some extent in the outcomes meas-
ured in pre-clinical studies (Table  4). However, studies 
typically measured only 1 or 2 outcomes and no single 
study reported more than seven outcomes in the COS 
(Fig. 2). Similar patterns were observed in clinical trials, 
registered prior to the publication of the COS, although 
a larger proportion of trials measured multiple core out-
comes. In pre-clinical studies there were multiple out-
comes reported that could be used to measure a core 
outcome (Table 4). Furthermore within these there were 
multiple methods of assessment. For example, “glycaemic 
control” was reported in 40 studies using four different 
outcomes of which glycated haemoglobin (HbA1c) was 
the most frequently measured (35/40 studies). There are 
four, commonly used, methods for the measurement of 
HbA1c [25], details of the method used were reported in 
29/35 papers. Each of the four methods was used at least 
once with immunoassay used most frequently (n = 18) 
followed by, ion-exchange high-performance liquid chro-
matography (HPLC) (n = 4), boronate affinity HPLC 
(n = 6), and enzymatic assays (n = 1), highlighting the 
variability in “how” outcomes are measured.
Outcomes in the COS that were not reported, or infre-
quently reported, represented longer term outcomes 
associated with morbidities (nephropathy, neuropathy, 
retinopathy, cardiovascular and cerebrovascular disease) 
resulting from long term insulin resistance [26]. Meas-
uring such complications in otherwise healthy, usually 
adolescent laboratory mice where the rates of spontane-
ous development of these complications of diabetes is 
low would bring some challenges, including the ethical 
and resource costs of the longer duration of experiments 
which would be required.
Discussion
Addressing methodological issues in pre-clinical research 
will help researchers take one step closer to achieving 
successful translation of safe and effective treatments 
[12, 27, 28]. However, the issue of outcome heterogene-
ity in pre-clinical studies, demonstrated here for type 2 
diabetes, has been overlooked, impacting on the ability to 
synthesise evidence, contributing to research waste and 
widening the translational gap.
Initiatives to harmonise outcomes have focused on 
later phase effectiveness trials [2, 24] yet there is potential 
to apply COS across the research pathway. In the case of 
type 2 diabetes, over 70% of the existing COS was meas-
ured, to some extent, in publications using pre-clinical 
mouse models. Discordance was observed for outcomes 
relating to long term complications but these too were 
infrequently measured in clinical trials with “gangrene 
and amputation of the leg, foot or toe”, and “cerebrovas-
cular disease” not measured at all and “deterioration of 
vision” and “myocardial infarction” each measured in 
a single clinical trial [21]. There were also limits of the 
pre-clinical search strategy which excluded studies that 
used specific mouse models of a long term diabetes com-
plication. Mice display a different rate of development/
aging to humans that cannot easily be converted between 
species [29, 30]; consequently, disease progression and 
time to the onset of long term complications may not be 
Some outcomes have been coded twice based on the context of measurement. Specifically total protein has been coded as ‘general outcomes’ and, where the reason 
for measurement was specified, this has been coded as ‘renal and urinary outcomes’
One study measured alkaline phosphatase (ALP), aspartate aminotransferase (AST) and alanine aminotransferase (ALT) specifically in the context of renal function and 
so these outcomes have been coded in both the ‘hepatobiliary outcomes’ domain and for one study coded in the ‘renal and urinary outcomes’ domain
Phosphorylated c-Jun N-terminal kinase (p-JNK) expression has been coded as ‘general outcomes’ and also for one study as ‘endocrine’ where this was measured 
specifically in relation to pancreatic fibrosis
Table 3 (continued)
Outcome domain Pre‑clinical in vivo mouse studies Phase 3/4 clinical trials [20]
Total number of unique 
outcomes within domain 
(verbatim outcomes)
Number of studies 
reporting one or more 
outcomes in the domain 
(%)
Total number of unique 
outcomes within domain 
(verbatim outcomes)
Number of studies 
reporting one or more 
outcomes in the domain 
(%)
33. Personal circumstances 0 (0) 0 (0) 0 (0) 0 (0)
34. Economic 0 (0) 0 (0) 6 (6) 4 (2.9)
35. Hospital 0 (0) 0 (0) 3 (4) 3 (2.2)
36. Need for intervention 0 (0) 0 (0) 7 (24) 16 (11.6)
37. Societal/carer burden 0 (0) 0 (0) 0 (0) 0 (0)
38. Adverse events/effects 5 (29) 20 (7.1) 4 (46) 33 (23.9)
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feasible to assess unless a specific animal model, pre-dis-
posed to the development of such conditions, is used.
Whilst mouse models are the most frequently used pre-
clinical animal model, there are limitations in the physi-
ological assessments that can be undertaken. A review of 
large animal and non-human primate models may iden-
tify further overlap of outcomes with those assessed in 
phase 3/4 clinical trials due to the ability to perform par-
ticular physiological assessments in these larger animals.
Death is reported in clinical trials, either as a specific 
outcome or in the collection of serious adverse events, 
and is routinely recorded in clinical practice but in the 
pre-clinical setting it is widely accepted that “death as 
an endpoint to a procedure should be avoided as far as 
possible and replaced by earlier, humane endpoints” [31]. 
Instead, alternative surrogate outcomes for death may be 
more appropriate and alleviate terminal distress in mice 
whilst also capturing the core outcome [32, 33.]
In the present study we have applied surrogate mark-
ers of quality of life including “food and water intake”, 
measured in 39% of studies. Yet in these studies the 
reason for measurement was not specified and, in the 
case of some diabetes treatments, may indicate assess-
ment of a side effect of treatment (weight gain) or poly-
dipsia (a symptom of elevated blood glucose). Animal 
welfare encompasses an animal’s overall quality of life, 
taking into consideration its physical and psychologi-
cal health along with the suitability of living conditions 
that give the animal opportunity to exhibit natural behav-
iours. Assessment of welfare is a critical component of 
research involving animals but this may go unreported in 
study publications. This under-reporting is further com-
pounded by multiple methods of assessment and clarity 
is needed on how quality of life should be measured [34].
A COS has the potential to reduce the risk of outcome 
reporting bias, an issue that has been highlighted in both 
pre-clinical and clinical research [35, 36]. For a COS to 
contribute to reducing the risk of reporting bias there 
is an expectation that it is used in its entirety or that 
clear justification is made for why some outcomes have 
not been measured. It is important to recognise that it 
may not be practical, or indeed ethical, to measure the 
full set of core outcomes in every pre-clinical study and 
instead data on the core outcomes may be collected by 
Fig. 2 Proportion of pre‑clinical and clinical studies measuring one or more of the core outcomes
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the triangulation of data from multiple pre-clinical stud-
ies. Using glycaemic control as an example in the present 
study it is clear that not only are there different ways to 
define the outcome but, in the case of HbA1c, multiple 
methods of measurement. For pre-clinical studies to 
apply the COS there needs to be clear reporting on which 
of the outcomes will be measured, including reasons why 
outcomes are not assessed, together with consensus on 
“how” each of the core outcome should be measured and 
further work is warranted in this area.
Conclusion
The COS developed for type 2 diabetes shows a large 
overlap with outcomes already measured and reported 
in pre-clinical research using a mouse model of type 2 
diabetes. Application of the COS, using agreed methods, 
in both pre-clinical research and clinical trials will mean 
that the same outcomes are measured and reported as a 
minimum, across the research pathway, facilitating evi-
dence synthesis that has the potential to identify the most 
promising treatments.
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